✨ Free AI Report
Cellectar Biosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Cellectar Biosciences, Inc.
Company Research

Cellectar Biosciences, Inc.: Business Overview, Financials & Competitive Analysis

Cellectar Biosciences, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). Lead candidate approaching NDA/EMA filings with FDA Breakthrough designation and strong Phase 2b data positions Cellectar for near-term value inflection. Iopofosine I 131 has FDA Breakthrough Designation and a confirmed traditional accelerated approval pathway. The company reported 83.6% overall response rate and 13.5-month progression-free survival for iopofosine in relapsed/refractory.

What is Cellectar Biosciences, Inc.'s industry? Cellectar Biosciences, Inc. (cellectar.com) operates in Biotechnology - Radiopharmaceuticals & Oncology. AskCyborg classifies Cellectar Biosciences, Inc. under Biotechnology - Radiopharmaceuticals & Oncology in its company registry.

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer. The company plans to submit a Conditional Marketing Authorization...

7/ 10Strong

Cyborg Score thesis

Lead candidate approaching NDA/EMA filings with FDA Breakthrough designation and strong Phase 2b data positions Cellectar for...

Read the full analyst-debate transcript →
Industry Biotechnology - Radiopharmaceuticals & Oncology
3 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 7, 2026
AI-Verified Research
30+ Page Report

Get the Latest Cellectar Biosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Cellectar Biosciences, Inc.

AskCyborg analysts argue the bull and bear cases for Cellectar Biosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Cellectar Biosciences, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Cellectar Biosciences, Inc. Overview

Pro stress-test →

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer. The company plans to submit a Conditional Marketing Authorization application to the EMA for iopofosine I 131 in Waldenstrom's macroglobulinemia in Q3 2026, targeting potential European approval in early 2027.

Strategic Profile

Pro stress-test →

The company leverages its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to develop next-generation cancer cell-targeting treatments. Cellectar secured up to $140 million in financing led by Nantahala Capital to support a global confirmatory pivotal study in Q4 2026 and an NDA filing for accelerated approval of iopofosine I 131 in Waldenstrom macroglobulinemia.

Competitive Landscape

Pro stress-test →

Cellectar competes in the therapeutic radiopharmaceuticals and targeted oncology space with companies developing radiotherapies and PDC-based platforms. Key competitors include players focused on radiopharmaceuticals and targeted cancer therapies, though Cellectar's proprietary PDC platform and iopofosine I 131 with FDA Breakthrough designation provide differentiation in hematologic malignancy treatment.

Industry Context

Cellectar Biosciences, Inc. operates in Biotechnology - Radiopharmaceuticals & Oncology.

Key facts

Founded: N/A · Headquarters: Florham Park, US · Employees: N/A · Revenue: $0 · Market cap: N/A

What the analysts stress-tested

The top findings that survived the multi-agent debate for Cellectar Biosciences, Inc..

  • Phase 1b CLR 125 TNBC (triple negative breast cancer) study expected to begin dosing in Q1 2026 with interim data due mid-2026, expanding pipeline beyond hematologic malignancies into solid tumors.
  • Multi-year supply agreement with Ionetix to secure clinical- and commercial-scale Actinium-225 and Astatine-211 for targeted alpha therapies, including CLR-225 for solid tumors.
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Positive 12-month follow-on data from CLOVER WaM study with 83.6% overall response rate and 13.5-month progression-free survival
  • May 2026Completed up to $140 million oversubscribed financing led by Nantahala Capital to support confirmatory trials and FDA/EMA filings
  • +2 moreTrack every material event for Cellectar Biosciences, Inc. as it happens. Explore monitoring →
Get alerted when Cellectar Biosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Actinium PharmaceuticalsRadiopharmaceutical therapeutics for hematologic malignancies→Novartis LutatheraSomatostatin receptor-targeted radiopharmaceutical→Incyte CalquenceBTK inhibitor for Waldenstrom macroglobulinemia→

Compare Cellectar Biosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Cellectar Biosciences, Inc. operates in Biotechnology - Radiopharmaceuticals & Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Radiopharmaceuticals & Oncology research →
NEW · MCP server

Ask your AI assistant about Cellectar Biosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Cellectar Biosciences, Inc. and its top competitor on Cyborg Score”
“What did Cellectar Biosciences, Inc. do this quarter?”
“Is Cellectar Biosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Cellectar Biosciences, Inc. do?+
Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer. The company plans to submit a Conditional Marketing Authorization...
What is Cellectar Biosciences, Inc.'s Cyborg Score?+
Cellectar Biosciences, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Cellectar Biosciences, Inc.'s main competitors?+
Named competitors include Actinium Pharmaceuticals, Novartis Lutathera, Incyte Calquence. The full competitive landscape is in the AskCyborg report.
How can I get the full Cellectar Biosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Cellectar Biosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Cellectar Biosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.